187 related articles for article (PubMed ID: 12836015)
1. Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?
Kayser S; Watermann I; Rentzsch C; Weinschenk T; Wallwiener D; Gückel B
J Cancer Res Clin Oncol; 2003 Jul; 129(7):397-409. PubMed ID: 12836015
[TBL] [Abstract][Full Text] [Related]
2. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
[TBL] [Abstract][Full Text] [Related]
4. T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer.
Nijman HW; van Diest PJ; Poort-Keesom RJ; von Mensdorff-Pouilly S; Verstraeten RA; Kummer A; Meijer CJ; Melief CJ; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 2001 Jan; 94(1):114-20. PubMed ID: 11134836
[TBL] [Abstract][Full Text] [Related]
5. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.
Morse MA; Secord AA; Blackwell K; Hobeika AC; Sinnathamby G; Osada T; Hafner J; Philip M; Clay TM; Lyerly HK; Philip R
Clin Cancer Res; 2011 May; 17(10):3408-19. PubMed ID: 21300761
[TBL] [Abstract][Full Text] [Related]
6. Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.
Gückel B; Rentzsch C; Nastke MD; Marmé A; Gruber I; Stevanović S; Kayser S; Wallwiener D
J Cancer Res Clin Oncol; 2006 Apr; 132(4):265-74. PubMed ID: 16374613
[TBL] [Abstract][Full Text] [Related]
7. Immunological profiling of a panel of human ovarian cancer cell lines.
Carr TM; Adair SJ; Fink MJ; Hogan KT
Cancer Immunol Immunother; 2008 Jan; 57(1):31-42. PubMed ID: 17579858
[TBL] [Abstract][Full Text] [Related]
8. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
9. Correlation between expression of major histocompatibility complex class I and that of antigen presenting machineries in carcinoma cell lines of the pancreas, biliary tract and colon.
Imanishi T; Kamigaki T; Nakamura T; Hayashi S; Yasuda T; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Kobe J Med Sci; 2006; 52(3-4):85-95. PubMed ID: 16855371
[TBL] [Abstract][Full Text] [Related]
10. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
11. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.
Liu G; Ying H; Zeng G; Wheeler CJ; Black KL; Yu JS
Cancer Res; 2004 Jul; 64(14):4980-6. PubMed ID: 15256472
[TBL] [Abstract][Full Text] [Related]
12. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression.
Seliger B; Höhne A; Knuth A; Bernhard H; Ehring B; Tampé R; Huber C
Clin Cancer Res; 1996 Aug; 2(8):1427-33. PubMed ID: 9816317
[TBL] [Abstract][Full Text] [Related]
13. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
[TBL] [Abstract][Full Text] [Related]
14. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
[TBL] [Abstract][Full Text] [Related]
15. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
16. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
17. Gene transfer of human interferon gamma complementary DNA into a renal cell carcinoma line enhances MHC-restricted cytotoxic T lymphocyte recognition but suppresses non-MHC-restricted effector cell activity.
Schendel DJ; Falk CS; Nössner E; Maget B; Kressenstein S; Urlinger S; Tampé R; Gansbacher B
Gene Ther; 2000 Jun; 7(11):950-9. PubMed ID: 10849555
[TBL] [Abstract][Full Text] [Related]
18. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
